EP0663834A1 - Growth hormone releasing peptides - Google Patents
Growth hormone releasing peptidesInfo
- Publication number
- EP0663834A1 EP0663834A1 EP93921654A EP93921654A EP0663834A1 EP 0663834 A1 EP0663834 A1 EP 0663834A1 EP 93921654 A EP93921654 A EP 93921654A EP 93921654 A EP93921654 A EP 93921654A EP 0663834 A1 EP0663834 A1 EP 0663834A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- phe
- ala
- trp
- lys
- gln
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 101710119601 Growth hormone-releasing peptides Proteins 0.000 title description 2
- 102100033367 Appetite-regulating hormone Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 65
- 108010051696 Growth Hormone Proteins 0.000 claims abstract description 44
- 102000018997 Growth Hormone Human genes 0.000 claims abstract description 44
- 239000000122 growth hormone Substances 0.000 claims abstract description 44
- 125000006239 protecting group Chemical group 0.000 claims abstract description 17
- YMUAIJKCQCFCKS-SRVKXCTJSA-N (2s)-n-[(2s)-1-[(2s)-2-carbamoylpyrrolidin-1-yl]-1-oxo-3-(1h-pyrazol-5-yl)propan-2-yl]-5-oxopyrrolidine-2-carboxamide Chemical group NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CC=NN1 YMUAIJKCQCFCKS-SRVKXCTJSA-N 0.000 claims abstract description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 6
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims abstract description 5
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims abstract description 5
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 5
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 5
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Chemical group CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims abstract description 4
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 claims abstract description 4
- 241000124008 Mammalia Species 0.000 claims abstract description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical group NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 4
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 4
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 62
- 239000011347 resin Substances 0.000 claims description 31
- 229920005989 resin Polymers 0.000 claims description 31
- 238000010168 coupling process Methods 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 230000008878 coupling Effects 0.000 claims description 14
- 238000005859 coupling reaction Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 101100127285 Drosophila melanogaster unc-104 gene Proteins 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- SHDMMLFAFLZUEV-UHFFFAOYSA-N n-methyl-1,1-diphenylmethanamine Chemical compound C=1C=CC=CC=1C(NC)C1=CC=CC=C1 SHDMMLFAFLZUEV-UHFFFAOYSA-N 0.000 claims description 3
- XZWXFWBHYRFLEF-FSPLSTOPSA-N Ala-His Chemical group C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 XZWXFWBHYRFLEF-FSPLSTOPSA-N 0.000 claims description 2
- 108010070944 alanylhistidine Proteins 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 12
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract description 5
- 125000000217 alkyl group Chemical group 0.000 abstract description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract description 2
- 229910052799 carbon Inorganic materials 0.000 abstract description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 118
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 114
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 71
- 229910001868 water Inorganic materials 0.000 description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 229910004373 HOAc Inorganic materials 0.000 description 30
- -1 n- pentyl Chemical group 0.000 description 27
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 239000000203 mixture Substances 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- 229960000583 acetic acid Drugs 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 16
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 16
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 13
- 239000002253 acid Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 9
- 229920005654 Sephadex Polymers 0.000 description 9
- 239000012507 Sephadex™ Substances 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 239000012362 glacial acetic acid Substances 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical group NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 102100022831 Somatoliberin Human genes 0.000 description 6
- 101710142969 Somatoliberin Proteins 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 6
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 5
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 5
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
- 101001068640 Nicotiana tabacum Basic form of pathogenesis-related protein 1 Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 4
- 150000001408 amides Chemical group 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 4
- 230000001817 pituitary effect Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 3
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 2
- AYMLQYFMYHISQO-QMMMGPOBSA-N (2s)-3-(1h-imidazol-3-ium-5-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CN=CN1 AYMLQYFMYHISQO-QMMMGPOBSA-N 0.000 description 2
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- OOXKSUTUUWFMBF-UHFFFAOYSA-N 2-pyridin-4-ylpropanoic acid Chemical compound OC(=O)C(C)C1=CC=NC=C1 OOXKSUTUUWFMBF-UHFFFAOYSA-N 0.000 description 2
- ZDHKVKPZQKYREU-UHFFFAOYSA-N 4-(chloromethyl)pyridine;hydron;chloride Chemical compound Cl.ClCC1=CC=NC=C1 ZDHKVKPZQKYREU-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 206010007733 Catabolic state Diseases 0.000 description 2
- 206010013883 Dwarfism Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 101000868151 Rattus norvegicus Somatotropin Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 102000005157 Somatostatin Human genes 0.000 description 2
- 108010056088 Somatostatin Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 2
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 2
- 235000008206 alpha-amino acids Nutrition 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000001195 anabolic effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- MGZCCVPNCOIAAM-UHFFFAOYSA-N diethyl 2-(pyridin-4-ylmethyl)propanedioate Chemical compound CCOC(=O)C(C(=O)OCC)CC1=CC=NC=C1 MGZCCVPNCOIAAM-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 229960000553 somatostatin Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- RWLSBXBFZHDHHX-VIFPVBQESA-N (2s)-2-(naphthalen-2-ylamino)propanoic acid Chemical compound C1=CC=CC2=CC(N[C@@H](C)C(O)=O)=CC=C21 RWLSBXBFZHDHHX-VIFPVBQESA-N 0.000 description 1
- SAAQPSNNIOGFSQ-LURJTMIESA-N (2s)-2-(pyridin-4-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=NC=C1 SAAQPSNNIOGFSQ-LURJTMIESA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-butyl radical Chemical group [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- SRHDLCGRWILQIL-UHFFFAOYSA-N 2-pyridin-4-ylpropanoic acid;hydrochloride Chemical compound Cl.OC(=O)C(C)C1=CC=NC=C1 SRHDLCGRWILQIL-UHFFFAOYSA-N 0.000 description 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- FNFOMFMVOHBKHO-UHFFFAOYSA-N 3-(1h-imidazol-2-yl)propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCC1=NC=CN1 FNFOMFMVOHBKHO-UHFFFAOYSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- GAFBGRBPYCNUCH-UHFFFAOYSA-N 4-methylbenzyl radical Chemical compound [CH2]C1=CC=C(C)C=C1 GAFBGRBPYCNUCH-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000720950 Gluta Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- SGCGMORCWLEJNZ-UWVGGRQHSA-N His-His Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1NC=NC=1)C([O-])=O)C1=CN=CN1 SGCGMORCWLEJNZ-UWVGGRQHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 159000000021 acetate salts Chemical group 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- GUPWNYUKYICHQX-UHFFFAOYSA-N carbonobromidic acid Chemical compound OC(Br)=O GUPWNYUKYICHQX-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000007333 cyanation reaction Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- JVSPPFPIQBTKEL-UHFFFAOYSA-N diethyl 2-(pyridin-4-ylmethyl)propanedioate;pyridin-4-ylmethanol Chemical compound OCC1=CC=NC=C1.CCOC(=O)C(C(=O)OCC)CC1=CC=NC=C1 JVSPPFPIQBTKEL-UHFFFAOYSA-N 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 206010016165 failure to thrive Diseases 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 108010028295 histidylhistidine Proteins 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- MWHLCFYPFGFBQO-UHFFFAOYSA-N hydron;2-(1h-imidazol-5-yl)acetic acid;chloride Chemical compound Cl.OC(=O)CC1=CN=CN1 MWHLCFYPFGFBQO-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- AKRYBBWYDSDZHG-UHFFFAOYSA-N nitrosobis(2-oxopropyl)amine Chemical compound CC(=O)CN(N=O)CC(C)=O AKRYBBWYDSDZHG-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- HFRXJVQOXRXOPP-UHFFFAOYSA-N thionyl bromide Chemical compound BrS(Br)=O HFRXJVQOXRXOPP-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000004950 trifluoroalkyl group Chemical group 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- This invention relates to compounds which cause enhanced release of growth hormone in animals, pharmaceutical compositions containing the compounds and methods of using the compounds.
- GH Growth Hormone
- a mediator released from the pituitary causes physiologic and metabolic changes in the tissues of the body. Effects such as tissue growth, increased rate of protein synthesis, increased mobilization and use of fatty acids for energy, and decreased use of carbohydrates, have been attributed to GH secretion.
- a deficiency of GH has been associated with certain types of medical disorders, such as certain instances of dwarfism.
- GH is released and regulated by several natural secretagogues. In particular,
- GH is specifically released in response to growth hormone releasing hormone (GHRH), a 40-44 amino acid peptide which acts directly upon specific pituitary receptors to cause the release. Secretion of GH is inhibited by somatostatin (SRIF). GH is also released in vitro and in vivo by certain smaller exogenous peptides. Such peptides are described, for instance, in U.S. Patents 4,410,513; 4,839,344;
- this invention is a peptide compound comprising a hexa- to nonapeptide as described hereinafter by formula (I).
- This invention is also a pharmaceutical composition for causing the release of growth hormone which comprises a compound of formula (I) and a pharmaceutically acceptable carrier.
- This invention is further a method for causing the release of growth hormone, in vivo or in vitro, which comprises administering an effective amount of a compound of formula (I).
- This invention is also a method for treating pathologies caused by a deficiency in the release of growth hormone, or conditions in which the release of growth hormone is desirable.
- This invention discloses novel peptides which cause the release of growth hormone (GH). Although the precise mechanism of action is not known, these peptides are believed to act directly upon the pituitary to cause this effect.
- the compounds of the present invention are novel and generally show greater potency at promoting the release of GH due to the residues incorporated in the residues V and Y.
- This invention comprises compounds of formula (I): A-B-E-F-Ala-G-(D-Phe)-U-V-Y-Z ⁇ ) wherein A is H or an amino protecting group, or is absent when R 1 is H or C ⁇ _ 4 alkyl;
- B is Gly, Ala, ⁇ -Ala, PyrAla, Gin or Lys, or is absent, when R 1 is H or C ⁇ _
- E is absent or Het-(CR , 2) m CHR 1 (CR' 2 ) p CO;
- F is D-Trp(R 2 ), D-Nal or D-Phe(R 2 );
- G is Nal(R 2 ), Trp(R 2 ) or Phe(R 2 );
- U is Lys, Arg or Orn
- V is D- or L- Gin, NH(CR'2) n CO or, when Y and Z are absent, NH(CR' 2 )n-OH;
- Y is absent or Gly;
- Z is OR" or NR'R";
- R is H or Ci- 4 alkyl
- R 2 is H, F, Cl, Br, I or NO2;
- R' is H or C alkyl
- R" is H or CMalkyl
- m and n are 0 to 3
- p is 0 or 1; or a pharmaceutically acceptable salt thereof.
- Prodrugs are hydrates, complexes or prodrugs of the compounds of formula (I).
- Prodrugs arc considered to be any covalentiy bonded carriers which release the active parent drug according to formula (I) in vivo.
- E is His, PyrAla, ImAc or ImPr.
- F is D-Trp, ⁇ -D-Nal or D-Phe.
- V-Y-Z is Gln-NH or Gln-Gly-NH 2 .
- A-B-E is ImAc, His or Ala-His.
- U is Lys.
- Representative compounds of this invention are : ImPr-D-Trp-Ala-Trp-D-Phe-Lys-Gln-Gly-NH2; ImAc-D-Trp-Ala-Trp-D-Phe-Lys-Gln-NH2; ImAc-D-Phe-Ala-Phe-D-Phe-Lys-Gln-NH2;
- this invention includes each unique nonracemic compound or diastereomer which may be synthesized and resolved by conventional techniques, and all mixtures thereof.
- the meaning of any substituent at any one occurrence is independent of its meaning, or any other substituent's meaning, at any other occurrence, unless specified otherwise.
- amino acid means the D- or L- isomer of alanine (Ala), arginine (Arg), asparagine (Asn), aspartic acid
- Nal may be 2-naphthylalanine ( ⁇ -Nal) or 1- naphthylalanine ( ⁇ -Nal).
- Phe(R 2 ), T ⁇ p(R 2 ), Nal(R 2 ) and His(R 2 ) refer to the indicated amino acid substituted on the aromatic ring by the group R 2 .
- Ci-4alkyl as applied herein is meant to include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and t-butyl.
- Ci ⁇ alkyl additionally includes pentyl, n- pentyl, isopentyl, neopentyl and hexyl and the simple aliphatic isomers thereof.
- AT, or aryl, as applied herein means phenyl or naphthyl, or phenyl or naphthyl substituted by one to three moieties R 11 .
- R 11 may be Ci ⁇ alkyl, C ⁇ _ 4 alkoxy, Ci ⁇ alkthio, trifluoroalkyl, OH, CI, Br or I.
- Het indicates pyridyl, imidazolyl, pyrazolyl or thienyl.
- t-Bu refers to the tertiary butyl radical
- Boc refers to the t-butyloxycarbonyl radical
- Fmoc refers to the fluorenylmethoxycarbonyl radical
- Ph refers to the phenyl radical
- Cbz refers to the benzyloxycarbonyl radical
- BrZ refers to the o-bromobenzyloxycarbonyl radical
- C1Z refers to the o-chlorobenzyloxycarbonyl radical
- Bzl refers to the benzyl radical
- 4-MBzl refers to the 4-methyl benzyl radical
- Me refers to methyl
- Et refers to ethyl
- Ac refers to acetyl
- Alk refers to C ⁇ _4alkyl
- Nph refers to 1- or 2-naphthy
- ImAc refers to 4-imidazolylacetyl
- ImPr refers to 4-imidazolylpropanoyl
- PyrAla refers to 4- pyridylalanine
- PyrPr refers to 4-pyridylpropanoyl.
- DCC refers to dicyclohexylcarbodiimide
- DIC refers to diisopropylcarbodiimide
- DMAP refers to dimethylamino-pyridine
- DEEA refers to diisopropylethyl amine
- EDC refers to N-ethyl-N'(dimethylaminopropyl)- carbodiimid ⁇ .
- HOBt refers to 1-hydroxybenzotriazole
- THF tetrahydrofuran
- DIEA diisopropylethyla ine
- DMF dimethyl formamide
- Pd/C a palladium on carbon catalyst
- PPA 1-propanephosphonic acid cyclic anhydride
- DPPA diphenylphosphoryl azide
- BOP refers to benzotriazol-1- yloxy-tris(dimethylamino)-phosphonium hexafluorophosphate
- HF refers to hydrofluoric acid
- TEA refers to triethylamine
- TFA trifluoroacetic acid
- PCC pyridinium chlorochromate
- BHA a benzhydrylamine polystyrene resin
- CMR chloromethyl resin.
- Coupling reagents as used herein denote reagents which may be used to form peptide bonds. Typical coupling methods employ carbodiimides, activated anhydrides and esters and acyl halides. Reagents such as EDC, DCC, DPPA, PPA, BOP reagent and oxalyl chloride, optionally used in conjunction with HOBt and N- hydroxysuccinimide are typical.
- the compounds of this invention are prepared by conventional techniques of chemistry and peptide bond formation by coupling the various residues B, E, F, G, U, V and Y together to form a linear peptide, and, if necessary, modifying the carboxy or amino terminal group to add the group A and Z.
- Coupling methods to form peptide bonds are generally well known to the art and include both solid phase and solution phase synthesis. Typically, any sidechain reactive groups are protected as known in the art to prevent unwanted side reactions in the coupling process.
- this invention includes a process for preparing a compound of the formula:
- A, B, E, F, G, U, V, Y and Z are as defined for formula (I), which comprises a) coupling the protected amino acids corresponding to B, E, F, G, U, V, Y as defined in formula (I) to form a suitably protected compound of the formula: A-B'-E , -F-Ala-G , -(D-Phe)-U , -V , -Y , -Z' wherein
- A, B', E', F, G', U', V and Y' are A, B, E, F, G, U, V and Y as defined in formula (I) with any sidechain reactive groups protected;
- X is NR'R", OR", NH-T" or O-T";
- T" is a chloromethyl, hydroxymethyl, benzhydrylamine or methylbenzhydryl amine resin; b) removing any protecting groups and, if Z' is NH-T" or O-T", cleaving the peptide from the resin; and c) optionally forming a pharmaceutically acceptable salt thereof.
- the synthesis is commenced by attaching the required ( ⁇ -amino-protected) alpha-amino acid to the resin.
- the ⁇ -amino protecting group is an acid labile group, such as the Boc group
- the ⁇ -amino protecting group can be removed by a choice of acidic reagents, such as trifluoroacetic acid or hydrochloric acid solutions in an organic solvent, at room temperature.
- the ⁇ -amino protecting group is a base labile group, such as the Fmoc group
- the ⁇ -amino protecting group can be removed by a choice of a basic reagent, such as piperidine in an organic solvent, at room temperature.
- the next ( ⁇ -amino-protected) amino acid is coupled via its free carboxyl group to the free amino group.
- Each protected amino acid is reacted in about a three fold excess using an appropriate coupling reagent, typically in a solution of DMF or methylene chloride. Repeating the cycle of deprotection of the amino group and coupling, each of the remaining protected amino acids is coupled stepwise in the desired order.
- the desired peptide can be cleaved from the resin support by treatment with a suitable reagent, such as an acid.
- a suitable reagent such as an acid.
- hydrogen fluoride is used, since this reagent both cleaves the peptide from the resin and removes most common side-chain protecting groups.
- Modification of amino groups may be accomplished, if necerney, by alkylation, sulfonylation, cyanation or acylation as is generally known in the art.
- the carboxy terminal group may be modified, if necessary, by coupling to an amine to form an amide or by esterification. Solution synthesis for the formation of amide or peptide bonds is accomplished using conventional methods used to form amide bonds.
- the amine is coupled via its free amino group to an appropriate carboxylic acid substrate using a suitable carbodiimide coupling agent, such as N,N' dicyclohexyl carbodiimide (DCC), optionally in the presence of catalysts such as 1-hydroxybenzotriazole
- a suitable carbodiimide coupling agent such as N,N' dicyclohexyl carbodiimide (DCC)
- DCC dicyclohexyl carbodiimide
- a protected Boc-amino acid or Cbz-amino acid is treated in an anhydrous solvent, such as methylene chloride or tetrahydrofuran (THF), in the presence of a base, such as N-methyl morpholine, DMAP or a trialkylamine, with isobutyl chloroformate to form the "activated anhydride", which is subsequently reacted with the free amine of a second protected amino acid.
- the solution phase synthesis can proceed by sequential addition of the individual amino acid residues to form the linear peptide, or individual fragments may be synthesized and coupled together in a convergent fashion.
- the sidechain protecting groups may be removed simultaneously by treatment with hydrofluoric acid.
- the reactive functional groups of the sidechains of each synthetic fragment are suitably protected as known in the art. Suitable protective groups are disclosed in Greene, PROTECTIVE GROUPS IN ORGANIC CHEMISTRY, John Wiley and Sons, New York, 1981.
- a phthaloyl or Fmoc group or a suitably substituted alkyloxycarbonyl, benzyloxycarbonyl or benzyl group may be used for protection of an amino group.
- the Boc group is generally preferred for protection of an ⁇ -amino group.
- a t-Bu, cHex or benzyl ester may be used for the protection of the side chain carboxyl.
- a benzyl group or suitably substituted benzyl group is used to protect the mercapto group or the hydroxyl group.
- the tosyl group may be used for protection of the imidazolyl group and tosyl or nitro group for protection of the guanidino group.
- a suitably substituted benzyloxycarbonyl, silyl or benzyl group may also be used for the hydroxyl group. Suitable substitution of the benzyloxycarbonyl or benzyl protecting groups is ortho and/or para substitution with chloro, bromo, nitro or methyl, and is used to modify the reactivity of the protective group.
- the hydroxyl group of a heterocyclic carbinol is coverted to a suitable leaving group, such as a halogen (eg., by treatment with thionyl chloride or bromide) and reacted with the anion of a malonate ester. Hydrolysis, followed by decarboxylation produces the desired heterocyclic acid.
- R 1 is an amino group
- the heterocyclic acid may be converted to the acid bromide, brominated alpha to the carbonyl with thionyl bromide, and hydrolyzed to the alpha bromo carboxylic acid. Amination of the bromide produces the ⁇ -amino acid.
- the bromide may be converted to a hydroxyl group, oxidized and reductively aminated, for instance with ammonium chloride and sodium cyanoborohydride.
- Acid addition salts of the peptides are prepared in a standard manner in a suitable solvent from the parent compound and an excess of an acid, such as hydrochloric, hydrobromic, sulfuric, phosphoric, acetic, trifluoroacetic, maleic, succinic or methanesulfonic.
- the acetate salt form is especially useful.
- Certain of the compounds form inner salts or zwitterions which may be acceptable.
- Cationic salts are prepared by treating the parent compound with an excess of an alkaline reagent, such as a hydroxide, carbonate or alkoxide, containing the appropriate cation; or with an appropriate organic amine.
- Cations such as Li+, Na+, K+, Ca++, Mg++ and NH4+ are specific examples of cations present in pharmaceutically acceptable salts.
- This invention provides a pharmaceutical composition which comprises a compound according to formula (I) and a pharmaceutically acceptable carrier.
- the pharmaceutical composition includes an effective amount of the compound to stimulate release of growth hormone, however, the administration of multiple doses of a composition containing suboptimal amounts of the compound may also be useful.
- Pharmaceutical acceptable carrier are well known in the art and are disclosed, for instance, in SPROWL'S AMERICAN PHARMACY, Dittert, L. (ed.), J.B. Lippincott Co., Philadelphia, 1974, and REMINGTON'S PHARMACEUTICAL SCIENCES, Gennaro, A. (ed.), Mack Publishing Co., Easton, Pennsylvania, 1985.
- compositions of the compounds of formula (I) may be formulated as sterile solutions, suspensions or emulsions, or lyophilized powders for parenteral administration.
- Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use.
- the liquid formulation may be a buffered, isotonic, aqueous solution.
- suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or buffered sodium or ammonium acetate solution.
- Such formulation is especially suitable for parenteral administration, but may also be used for oral administration or contained in a metered dose inhaler or nebulizer for insufflation.
- compositions for nasal administration may additionally contain enhancers, such as bile acids.
- compositions for topical administration may also contain permeation enhancers, such as DMSO or formamide.
- these peptides may be encapsulated, tableted or prepared in a emulsion or syrup for oral administration.
- Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition.
- Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin.
- the amount of solid carrier varies but, preferably, will be between about 20 mg to about 1 g per dosage unit.
- the pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulating, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms.
- liquid carrier When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion or an aqueous or non-aqueous suspension. Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule.
- Liquid carriers include syrup, peanut oil, olive oil, saline and water.
- the carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
- the peptides of this invention may also be combined with excipients such as cocoa butter, glycerin, gelatin or polyethylene glycols and molded into a suppository.
- the compounds of this invention may be used to treat conditions in which growth hormone has been shown to exert a beneficial effect
- this invention provides a method of treating: 1) disease states wherein an insufficiency of endogenous GH is a factor, 2) catabolic states in which it is desirable to increase the level of circulating GH, 3) conditions in which it is beneficial to increase anabolic metabolism, or 4) enhanced development or production in commercial livestock.
- the method comprises administering a compound of formula (I) to a mammal in need thereof.
- the compounds of formula (I) may be used in the manufacture of a medicament.
- the peptide is administered either orally, parenterally, rectally or intranasally, to the patient, in a manner such that the concentration of drug in the plasma is sufficient to cause the release of growth hormone.
- the peptide is administered one to four times daily as is indicated by the effect being sought and the condition of the patient.
- the pharmaceutical composition containing the peptide is administered at a dose between about 0.01 to about 5000 ⁇ g/kg in a manner consistent with the condition of the subject, route of administration and species being treated. Typically, cows and humans require about the same dosages, while rats require a somewhat higher dose. About 0.1 to 20 ⁇ g/kg is a typical intravensous dose.
- An intravenous infusion of the peptide in 5% dextrose in water or normal saline is most effective, although an intramuscular bolus injection may be sufficient.
- a somewhat higher dose is used for oral administration, dosages in the range of 1 to 1000 ⁇ g/kg being useful, and in the range of 20 to 600 ⁇ g/kg being typical.
- the compounds of this invention may also be combined with other compounds and compositions which cause the release of GH. Such combinations will generally allow the use of lower dosages of each component to cause an equivalent amount of GH to be released.
- the compounds of this invention may be combined with growth hormone releasing hormone (GHRH) and its bioactive analogs and inhibitors of somatostatin (SRIF).
- GHRHs and analogues are disclosed, for instance, in U.S. Patents 4,517,181; 4,585,756; 4,605,643; 4,610,976; and 4,801,456, which are incorporated herein by reference.
- Other suitable growth hormone releasing components are disclosed in U.S. Patent No. 4,880,778, which is incorporated herein by reference.
- EC50 in rats for the compounds of this invention arc in the range of 2-30 ⁇ g/kg.
- Preferred compounds have EC50 less than 10 ⁇ g kg.
- His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 has an EC50 of about 42 ⁇ g/kg in the assay described hereinafter.
- 20 ⁇ L of plasma (or a rat Growth Hormone standard) was diluted to 500 ⁇ L with assay buffer, and incubated at room temperature overnight with 100 ⁇ L 125 I-rat- Growth Hormone (Chemicon Corp., Temecula, CA; -20,000 cpm/tube) and 200 ⁇ L of monkey anti-rat Growth Hormone antiserum (diluted 1 :4000 with Ab buffer; Pituitary Hormones and Antisera Center, Torranc ⁇ , CA). On the following day, 200 ⁇ L of goat anti-monkey antisera (1:10 dilution P4; Antibodies Inc., Davis, CA) was added to each tube and the tubes were incubated for 2-4 h at room temperature.
- the assay tubes were then centrifuged (5000xG, 30 min), the supernatant was aspirated, and the resulting pellet was counted for radioactivity in a Packard Gamma Counter.
- the Growth Hormone content was calculated from the rat Growth Hormone standard curve. The lower limit of detection was 0.1 ng-GH/mL-plasma.
- ODS refers to an octadecylsilyl derivatized silica gel chromatographic support.
- Sephadex® is a cross-linked poly(dextran) manufactured by Pharmacia Fine Chemicals, Piscataway, N.J.
- PRP-1® is a polymeric (styrene- divinyl benzene) chromatographic support and is a registered trademark of Hamilton Co., Reno, Nevada.
- BondElut® C18 is an octadecyl silica manufactured Varian Associates, Palo Alto, California.
- Peptide amides were synthesized by solid phase peptide synthesis using benzhydrylamine resin as the support. Protected amino acids were added sequentially starting from the carboxyl terminus until the desired sequence was obtained. The t- butyloxycarbonyl (Boc) group was used for protection of the alpha-amino group.
- Imidazoleacetic acid hydrochloride (3 eq) is dissolved in 15 mL DMF with warming. This is added to the neutralized, free amine peptidyl resin, followed by DIC (3 eq) in CH2CL2 (15 mL), HOBt (3 eq) in DMF (5 mL) and then DIEA (3 eq).
- DIC 3 eq
- HOBt 3 eq
- DMF 5 mL
- DIEA DIEA
- coupling is carried out using ImAc»HCl in DMF followed by DIC (3 eq) and DMAP (3 eq) in CH 2 CI 2 (15 mL) and then DIEA (3 eq).
- Boc-Ala-His(Cbz)-D-T ⁇ p-Ala-Trp-D-Phe-Lys(ClZ)-Gln-Gly-BHA resin (0.5 mmol) was treated with a mixture of HF (10 mL) and anisole (1 mL) at 0°C for 1 h. After removal of HF by a stream of N2 and drying under vacuum, the resin was washed with ether, air-dried and extracted with glacial acetic acid (3 x 30 mL). The acetic acid extracts were combined and lyophilized to give crude peptide (586 mg).
- the crude peptide (480 mg) was dissolved in 0.1% TF A water (3 mL) and chromatographed (BondElut Ci8, prewashed with 0.1 % TFA/acetonitrile followed by 0.1% TFA water, step gradient, 0.1% TFA/water, 20% acetonitrile/water-0.1% TFA, 40% acetonitrile/water-0.1% TFA).
- the 20% acetonitrile/water-0.1% TFA fraction was evaporated to dryness and lyophilized from 1% HOAc/water to yield a partially purified peptide (285 mg). An aliquot (100 mg) of the partially purified peptide was dissolved in 1 %
- the crude peptide was dissolved in 0.1 % TFA/water (3 mL) and chromatographed (BondElut Cis, prewashed with 0.1% TFA acetonitrile followed by 0.1% TFA water, step gradient, 0.1% TFA/water, 20% acetonitrile/water-0.1% TFA, 40% acetonitrile/water-0.1% TFA).
- the 20% acetonitrile/0.1% TFA fraction was evaporated to dryness and lyophilized from 1% HO Ac to yield partially purified peptide (171 mg).
- Boc-His(Cbz)-D-Trp-Ala-Trp-D-Phe-Lys(ClZ)-Gln-Gly-BHA resin (1.0 mmol) was treated with a mixture of HF (10 mL) and anisole (1 mL) at 0°C for 1 h. After removal of HF by a stream of N2 and drying under vacuum, the resin was washed with ether, air-dried and extracted with glacial acetic acid (3 x 30 mL). The acetic acid extracts were combined and lyophilized to give a crude peptide (1.20 g).
- ImAc-D-Trp-Ala-Trp-D-Phe-Lys(ClZ)-Gln-Gly-BHA resin (1.0 mmol) was treated with a mixture of HF (10 mL) and anisole (1 mL) at 0°C for 1 h. After removal of HF by a stream of N2 and drying under vacuum, the resin was washed with ether, air-dried and extracted with glacial acetic acid (3 x 30 mL). The acetic acid extracts were combined and lyophilized to give crude peptide (1.2 g).
- Boc-His(Cbz)-D-Trp-Ala-Trp-D-Phe-Lys(ClZ)-Gln-BHA resin (0.5 mmol) was treated with a mixture of HF (10 mL) and anisole (1 mL) at 0°C for 1 h. After removal of HF by a stream of N2 and drying under vacuum, the resin was washed with ether, air-dried and extracted with glacial acetic acid (3 x 30 mL). The acetic acid extracts were combined and lyophilized to give crude peptide (579 mg). Crude peptide (480 mg) was dissolved in 0.1% TFA/water (3 mL) and chromatographed (BondElut Cis, prewashed with 0.1% TFA/acetonitrile followed by
- the crude peptide was dissolved in 0.1% TFA water (6 mL) and aliquots (3 mL) were chromatographed (BondElut Cis, prewashed with 0.1% TFA/acetonitrile followed by 0.1% TFA/water, step gradient, 0.1% TFA/water, 20% acetonitrile/water- 0.1% TFA, 40% acetonitrile/water-0.1% TFA). The 20% acetonitrile/0.1% TFA fractions were combined, evaporated to dryness and lyophilized from 1% HOAc to yield partially purified peptide (376 mg).
- a parenteral dosage form containing 100 ⁇ g/mL of drug is prepared as follows:
- Example 1 1 mg of the compound of Example 1 is dissolved in 10 mL normal sterile saline solution and the pH is adjusted to 5.0 with either acetic acid or sodium hydroxide. This solution is filtered through a 0.5 ⁇ filter into a sterile ampoule, the head space is filled with nitrogen and the ampoule is capped with a rubber septum.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95150092A | 1992-09-25 | 1992-09-25 | |
US951500 | 1992-09-25 | ||
PCT/US1993/008805 WO1994007519A1 (en) | 1992-09-25 | 1993-09-17 | Growth hormone releasing peptides |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0663834A1 true EP0663834A1 (en) | 1995-07-26 |
EP0663834A4 EP0663834A4 (en) | 1996-01-24 |
Family
ID=25491752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP93921654A Withdrawn EP0663834A4 (en) | 1992-09-25 | 1993-09-17 | Growth hormone releasing peptides. |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0663834A4 (en) |
JP (1) | JPH08502250A (en) |
WO (1) | WO1994007519A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5872100A (en) * | 1990-05-11 | 1999-02-16 | Deghenghi; Romano | Peptides containing D-2-Alkyl-Tryptophan |
CA2179597A1 (en) * | 1993-12-23 | 1995-06-29 | Nils Langeland Johansen | Compounds with growth hormone releasing properties |
CZ291798B6 (en) * | 1994-09-27 | 2003-05-14 | Romano Deghenghi | Peptides, their use and pharmaceutical composition in which the peptides are comprised |
DE69637855D1 (en) * | 1995-12-22 | 2009-04-16 | Novo Nordisk As | CONNECTIONS WITH GROWTH HORMONE RELEASING PROPERTIES |
US6451970B1 (en) | 1996-02-21 | 2002-09-17 | Novo Nordisk A/S | Peptide derivatives |
JP2002525265A (en) | 1998-08-14 | 2002-08-13 | アドミニストレイターズ オブ ザ トゥレーン エジュケーショナル ファウンド | Compound having growth hormone releasing activity |
US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
US20170121385A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL98910A0 (en) * | 1990-07-24 | 1992-07-15 | Polygen Holding Corp | Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them |
-
1993
- 1993-09-17 JP JP6509101A patent/JPH08502250A/en active Pending
- 1993-09-17 WO PCT/US1993/008805 patent/WO1994007519A1/en not_active Application Discontinuation
- 1993-09-17 EP EP93921654A patent/EP0663834A4/en not_active Withdrawn
Non-Patent Citations (2)
Title |
---|
PEPTIDE RESEARCH, vol. 2, no. 1, 1989 pages 140-46, T.K.SAWYER ET AL. 'Discovery and Structure-Activity Relationships of Novel alpha-Melanocyte-Stimulating Hormone Inhibitors' * |
See also references of WO9407519A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1994007519A1 (en) | 1994-04-14 |
JPH08502250A (en) | 1996-03-12 |
EP0663834A4 (en) | 1996-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI92211B (en) | Process for the preparation of therapeutically useful nonapeptide and decapeptide analogues, which are LHRH antagonists | |
US6242563B1 (en) | Peptide analogues | |
US6143722A (en) | Heptapeptide oxytocin analogues | |
JP2010189398A (en) | Peptide analogue of pacap | |
US5861379A (en) | Chimeric fatty body-pro-GRF analogs with increased biological potency | |
JP5254868B2 (en) | Somatostatin-Dopamine Chimeric Analog | |
EP0097031B1 (en) | Nonapeptide and decapeptide analogs of lhrh useful as lhrh antagonists, their preparation and compositions containing them | |
AU755852B2 (en) | GRF analogs with increased biological potency | |
US4690916A (en) | Nona and decapeptide analogs of LHRH useful as LHRH antagonists | |
HU213098B (en) | Process for producing decapeptides antagonistic to hormone for releazing lutheinizing-hormone and pharmaceutical compositions containing them as active components | |
PL186520B1 (en) | Compunds exhibiting growth hormone liberating properties | |
US6057422A (en) | Antagonistic analogs of GH-RH inhibiting IGF-I and -II | |
RU2335506C2 (en) | Peptide analogues gh-rh with opposing action, way of depression of gh level, way of depression of igf-inigf-ii level, application for inhibition of growth of cancer cells, pharmacologically acceptable composition (variants) | |
JP2000510453A (en) | Compounds having growth hormone releasing properties | |
EP0663834A1 (en) | Growth hormone releasing peptides | |
Theobald et al. | Novel gonadotropin-releasing hormone antagonists: peptides incorporating modified N. omega.-cyanoguanidino moieties | |
JP2927936B2 (en) | Peptides | |
JPH08505611A (en) | LHRH antagonist having modified aminoacyl residues at the 5th and 6th positions | |
JP6113144B2 (en) | Growth hormone releasing factor (GRF) analogs and uses thereof | |
PL195917B1 (en) | Novel peptides - analogues of a human hormone responsible for release of the growth hormone | |
JPH01199997A (en) | Peptide acting on pituitary of mannal | |
NZ544157A (en) | Pharmaceutical composition comprising cyclic somatostatin analogues | |
KR0142195B1 (en) | Competitive genadoliberin antagonists | |
JPH0393796A (en) | Ghrh analogous compound | |
JPH04210998A (en) | Inhibition of endotherial ion secretion from digestive tract by peptide derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19950321 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE FR GB IT LI NL |
|
RHK1 | Main classification (correction) |
Ipc: A61K 37/02 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19951205 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): BE CH DE FR GB IT LI NL |
|
17Q | First examination report despatched |
Effective date: 19970505 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19971118 |